The Potential Impact of Coagulation Factor XIII in Trauma-induced Coagulopathy - a Retrospective Case Series Analysis

Overview

Journal Eur J Trauma Emerg Surg

Specialties Critical Care
Emergency Medicine

Date 2023 Jan 20

PMID 36670303

Authors

Michaela Wilhelmi

Alexander Albrecht

Christian Macke

Mathias Wilhelmi

Mohammed Omar

Marcel Winkelmann

Jan-Dierk Clausen

Affiliations

Soon will be listed here.

Abstract

Background: The role of factor XIII (FXIII) in trauma-induced coagulopathy (TIC) is not fully understood.

Methods: We evaluated FXIII supplementation in severely injured patients with persistent bleeding. This was a retrospective case series analysis.

Results: Twenty-four patients received FXIII concentrate within 24 h of admission for bleeding that continued after transfusion of > 6 U red blood cells (RBCs); control patients (n = 27) did not receive FXIII concentrate. Both study groups were similar regarding injury severity score and global coagulation tests, but FXIII activity levels were significantly higher and lactate levels significantly lower in the control group, respectively. The differences in FXIII activity between the groups could be attributed to a more severe trauma-induced coagulopathy in FXIII-deficient patients, as demonstrated by lower fibrinogen and higher lactate levels. The median dose of FXIII concentrate within 24 h of admission was 2500 IU (IQR: 1250-4375). Median 24-h transfusion of RBCs (primary study endpoint) was significantly higher in the FXIII group versus controls (10.0 U, IQR 5-14 U vs. 2, IQR 0-6 U; p < 0.01). Subsequently, while patients were in the intensive care unit, there was no statistically significant difference regarding RBC transfusion anymore and the overall clinical outcomes were similar in both patient groups.

Conclusions: The substitution of FXIII in patients who were more seriously compromised due to higher lactate levels and who presented with initially more severe bleedings than patients in the control group, resulted in a comparable transfusion necessity after 24 h. Thus, we guess that the substitution of FXIII in severely injured patients with ongoing bleeding might have an impact on their clinical outcome.

References

Gerlach R, Tolle F, Raabe A, Zimmermann M, Siegemund A, Seifert V . Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: implications of a prospective study. Stroke. 2002; 33(6):1618-23. DOI: 10.1161/01.str.0000017219.83330.ff. View

Peyvandi F, Palla R, Menegatti M, Siboni S, Halimeh S, Faeser B . Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012; 10(4):615-21. DOI: 10.1111/j.1538-7836.2012.04653.x. View

Ivaskevicius V, Seitz R, Kohler H, Schroeder V, Muszbek L, Ariens R . International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost. 2007; 97(6):914-21. View

Schlimp C, Cadamuro J, Solomon C, Redl H, Schochl H . The effect of fibrinogen concentrate and factor XIII on thromboelastometry in 33% diluted blood with albumin, gelatine, hydroxyethyl starch or saline in vitro. Blood Transfus. 2012; 11(4):510-7. PMC: 3827394. DOI: 10.2450/2012.0171-12. View

Kleber C, Sablotzki A, Casu S, Olivieri M, Thoms K, Horter J . The impact of acquired coagulation factor XIII deficiency in traumatic bleeding and wound healing. Crit Care. 2022; 26(1):69. PMC: 8943792. DOI: 10.1186/s13054-022-03940-2. View

Spahn D, Bouillon B, Cerny V, Duranteau J, Filipescu D, Hunt B . The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care. 2019; 23(1):98. PMC: 6436241. DOI: 10.1186/s13054-019-2347-3. View

Levy J, Goodnough L . How I use fibrinogen replacement therapy in acquired bleeding. Blood. 2014; 125(9):1387-93. DOI: 10.1182/blood-2014-08-552000. View

Godje O, Gallmeier U, Schelian M, Grunewald M, Mair H . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thorac Cardiovasc Surg. 2006; 54(1):26-33. DOI: 10.1055/s-2005-872853. View

Stein P, Kaserer A, Sprengel K, Wanner G, Seifert B, Theusinger O . Change of transfusion and treatment paradigm in major trauma patients. Anaesthesia. 2017; 72(11):1317-1326. DOI: 10.1111/anae.13920. View

10.

Innerhofer P, Fries D, Mittermayr M, Innerhofer N, von Langen D, Hell T . Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol. 2017; 4(6):e258-e271. DOI: 10.1016/S2352-3026(17)30077-7. View

11.

Listyo S, Forrest E, Graf L, Korte W . The Need for Red Cell Support During Non-Cardiac Surgery Is Associated to Pre-Transfusion Levels of FXIII and the Platelet Count. J Clin Med. 2020; 9(8). PMC: 7465630. DOI: 10.3390/jcm9082456. View

12.

DUCKERT F, Jung E, SHMERLING D . A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh. 1960; 5:179-86. View

13.

Gerlach R, Raabe A, Zimmermann M, Siegemund A, Seifert V . Factor XIII deficiency and postoperative hemorrhage after neurosurgical procedures. Surg Neurol. 2000; 54(3):260-4; discussion 264-5. DOI: 10.1016/s0090-3019(00)00308-6. View

14.

Theusinger O, Baulig W, Asmis L, Seifert B, Spahn D . In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM). Thromb Haemost. 2010; 104(2):385-91. DOI: 10.1160/TH09-12-0858. View

15.

Katzensteiner M, Ponschab M, Schochl H, Oberladstatter D, Zipperle J, Osuchowski M . Factor XIII Measurement and Substitution in Trauma Patients after Admission to an Intensive Care Unit. J Clin Med. 2022; 11(14). PMC: 9317588. DOI: 10.3390/jcm11144174. View

16.

SHAINOFF J, Estafanous F, Yared J, Dibello P, Kottke-Marchant K, Loop F . Low factor XIIIA levels are associated with increased blood loss after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1994; 108(3):437-45. View

17.

Richardson V, Cordell P, Standeven K, Carter A . Substrates of Factor XIII-A: roles in thrombosis and wound healing. Clin Sci (Lond). 2012; 124(3):123-37. DOI: 10.1042/CS20120233. View

18.

von Rappard S, Hinnen C, Lussmann R, Rechsteiner M, Korte W . Factor XIII Deficiency and Thrombocytopenia Are Frequent Modulators of Postoperative Clot Firmness in a Surgical Intensive Care Unit. Transfus Med Hemother. 2017; 44(2):85-92. PMC: 5425767. DOI: 10.1159/000468946. View

19.

Duque P, Chasco-Ganuza M, Ortuzar A, Almaraz C, Terradillos E, Perez-Rus G . Acquired FXIII Deficiency is Associated with High Morbidity. Thromb Haemost. 2021; 122(1):48-56. DOI: 10.1055/a-1481-2733. View

20.

Dickneite G, Herwald H, Korte W, Allanore Y, Denton C, Cerinic M . Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions. Thromb Haemost. 2015; 113(4):686-97. DOI: 10.1160/TH14-07-0625. View